TAmiRNA presents translational perspectives of microRNA bone biomarkers at Sheffield workshop


TAmiRNA presents translational perspectives of microRNA bone biomarkers at Sheffield workshop


tamirna_logo

Press Release | TAmiRNA GmbH

OCTOBER 16, 2017

Vienna, Austria: – Innovative biotech company TAmiRNA will present its latest insights on new applications of circulating microRNAs as novel biomarkers at a specialist workshop on bone diseases at University of Sheffield UK.

TAmiRNA CEO Dr. Matthias Hackl is one of a list of eminent speakers from across Europe addressing the Mellanby Centre Workshop on Non-coding RNAs in Bone and Cartilage this month.

The workshop organized by the Mellanby Centre for Bone Research, based in the University of Sheffield’s Medical School.

Regulation of bone turnover

Dr. Hackl will address the workshop on the “Intra- and extracellular microRNAs and bone: translational perspectives” during the first day of the conference on Thursday, October 19th (15:15 – 15:45 hrs.).

“I will discuss how we can translate known and novel biological functions of microRNAs in bone physiology/health versus bone disease for biomarker R&D by sharing results from in vitro as well as in vivo studies from the last years performed in our lab, but also other labs. I will also focus on some technical details that I find important for circulating microRNA analysis,” said Dr. Hackl.

Novel biomarkers

“We are looking forward to this valuable opportunity to connect with a highly expert and influential audience of biotech and pharma scientists participating in clinical studies at academia and at clinical research groups,” said Dr. Hackl.

We will be able to present a series of novel biomarker candidates for predicting fracture risk in osteoporosis with further possibilities of identifying high-risk subsets that qualify for preventive therapeutic treatment. These new biomarker targets also give insights into the disease mechanism of osteoporosis,” he added.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com

About Mellanby Centre Workshop

The Mellanby Centre for Bone Research was established in 2009 to establish a focus for bone research at the University of Sheffield, foster inter-disciplinary research, develop collaborative research programmes and grant applications and develop links with the pharmaceutical and biotechnology industry. The Centre promotes a world-class translational programme of basic and clinical bone research with a wide-ranging and comprehensive remit, making it unique in the UK and one of only a small number of bone disease institutes worldwide.

As a dynamic institution at the forefront of bone research, The Mellanby Centre hosts international speakers at its regular Research Seminar Series and topic-focused workshops.

The Mellanby Centre Non-coding RNAs in Bone and Cartilage Workshop is a two-day event opening October 19, 2017, at Halifax Hall, University of Sheffield, featuring a list of eminent speakers from across Europe.

The workshop s organized by the Mellanby Centre in partnership with University of Sheffield with more information available at http://medicine.dept.shef.ac.uk/news/ and at http://mellanbycentre.org/news-and-events/.

Media Contact

Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56
Email: office@tamirna.com

Resources

Click on TAmiRNA presents translational perspectives of microRNA bone biomarkers for other information.
Click on TAmiRNA to contact the company directly.

Dr. Matthias Hackl, CEO, TAmiRNA GmbH

Dr. Matthias Hackl, CEO, TAmiRNA GmbH



Supplier Information
Supplier: TAmiRNA GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 (0)660 420 58 56
Website: www.tamirna.com


Comments are closed.